Ki-67 (MIB-1) (NET Pancreas (8th 2018-2023))

Organization	Field Name	ID#	ID Name	Required

Organization	Field Name	ID#	ID Name	Required
KCR	Ki-67	34060	Ki67	yes
SEER	Ki-67 (MIB-1)	3863	ki67	yes

Note 1 Effective years

Note 2 Physician Statement

Physician statement of Ki-67 (MIB-1), also referred to as the “Proliferative Index,” can be used to code this data item when no other information is available

Note 3 Priority order

A specific value (0.0-100.0) takes priority over XXX.4, XXX.5 or XXX.6.
Code the exact percentage when provided
When the exact percentage is not given, including ranges or terms such as “less than” or “greater than” use the range value codes XXX.4, XXX.5, XXX.6.
XXX.4, XXX.5 and XXX.6 were added since they are listed on the CAP protocol

Note 4 Results from nodal or metastatic tissue

May not be used
If the only information you have is a Ki-67 from a metastatic site, code to XXX.9

Note 5 Neoadjuvant Therapy

Record the assay from tumor specimens prior to neoadjuvant therapy.
If neoadjuvant therapy is given and there are no HER2 ISH results from pre-treatment specimens, report the findings from post-treatment specimens.

Code	Description

Code	Description
0.0-100.0	0.0 to 100.0 percent positive: enter percent positive
XXX.4	Ki-67 stated as less than 3%
XXX.5	Ki-67 stated as 3%-20%
XXX.6	Ki-67 stated as greater than 20%
XXX.7	Test done; actual percentage not stated
XXX.8	Not applicable: Information not collected for this case (If this item is required by your standard setter, use of code XXX.8 will result in an edit error.)
XXX.9	Not documented in medical record Ki-67 (MIB-1) not assessed or unknown if assessed
<BLANK>	Must be blank if diagnosis year is before 2021

KCR Abstractors Manual